In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced disease progression or death at 45 d
Sign Up to like & getrecommendations! Published in 2023 at "Annals of Internal Medicine"
DOI: 10.7326/j22-0118
Abstract: SOURCE CITATION Eikelboom JW, Jolly SS, Belley-Cote EP, et al. Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respir Med. 2022;10:1160-8. 36228639. read more here.
Keywords: covid neither; risk outpatients; high risk; colchicine ... See more keywords